← Browse by Condition
Medical Condition
refractory non hodgkin lymphoma
Total Trials
3
Recruiting Now
3
Trial Phases
Phase 2, Phase 1
NCT05260957 Phase 2
Recruiting
CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).
Enrollment
22 pts
Location
United States
Sponsor
Lazaros Lekakis
NCT07166419 Phase 1
Recruiting
Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia
Enrollment
24 pts
Location
United States
Sponsor
Ohio State University Comprehe...
NCT06484920 Phase 2
Recruiting
A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL
Enrollment
24 pts
Location
United States
Sponsor
Rita Assi